与中重度斑块状银屑病中阿达木单抗和英夫利昔单抗反应相关的多态性
Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
作者信息
Ovejero-Benito María C, Prieto-Pérez Rocío, Llamas-Velasco Mar, Muñoz-Aceituno Ester, Reolid Alejandra, Saiz-Rodríguez Miriam, Belmonte Carmen, Román Manuel, Ochoa Dolores, Talegón María, Cabaleiro Teresa, Daudén Esteban, Abad-Santos Francisco
机构信息
Department of Clinical Pharmacology, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), E28006, Madrid, Spain.
Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), E28006, Madrid, Spain.
出版信息
Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.
AIM
This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab.
MATERIALS & METHODS: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis.
RESULTS
Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months.
CONCLUSION
Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
目的
本研究评估了药物遗传学对接受阿达木单抗和/或英夫利昔单抗治疗的银屑病患者的影响。
材料与方法
前瞻性观察性研究，评估124个多态性与中重度斑块状银屑病患者在治疗3个月（n = 95）和6个月（n = 90）时对阿达木单抗或英夫利昔单抗反应（PASI75）的相关性。对单变量分析中有意义的单核苷酸多态性（SNP）进行多变量分析。
结果
5个SNP在3个月时与PASI75相关：rs6661932（IVL）、rs2546890（IL-12B）、rs2145623（NFKBIA）、rs9304742（ZNF816A）和rs645544（SLC9A8）。此外，rs1061624（TNFR1B）在6个月时与PASI75相关。
结论
然而，在临床实践中应用这些生物标志物之前，应在大规模研究中对其进行验证。
Zotero 插件